The global blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7% from 2016 to 2021. The major factors driving the growth of this market are increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid amplification test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=267747042
This report segments the blood screening market on the basis of technology, product & service, end user, and region. Based on technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment is further subsegmented into TMA and real-time PCR. The ELISA technology segment is further categorized into various generations and platforms. On the basis of generation, the ELISA segment is further divided into first generation ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA. On the basis of platform, the ELISA segment is categorized into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI).
The NAT segment is expected to dominate the global blood screening market in 2016. This growth can be attributed to the increasing number of blood donations, rising prevalence/incidence of infectious diseases, and increasing capacity (disposable income) to pay for NAT-tested blood. Moreover, the rising awareness about innovative and advanced applications of NAT in disease screening and the increasing demand for safe donated blood by patients suffering from sickle-cell anemia, thalassemia, and hemophilia serve to support the growth of this technology segment.
On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is further subsegmented into NAT, ELISA, and other reagents and kits. The instrument segment is categorized based on purchase mode and is further subsegmented into rental purchase and outright purchase. In 2016, the reagents and kits segment is expected to account for the largest share of the blood screening market. The large share of this segment can be attributed to the high consumption and repeated use of reagents and kits in blood screening procedures.
On the basis of end user, the blood screening market is segmented into blood banks and hospitals. The blood banks segment is expected to account for the largest share of the market in 2016. Major factors driving the growth of this segment are the increasing demand for donated blood, growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing number of donations worldwide, and growth in government funding to charitable trusts.
On the basis of region, the blood screening market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. Growth in this regional segment is driven by factors such as increasing adoption of nucleic acid tests (NAT) and increasing participation of various government associations in blood donations and screening & transfusion activities.
Key players in the blood screening market include Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers (Germany), Abbott Laboratories (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), and Beckman Coulter, Inc. (U.S.).
To Know More @ https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
